We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+10.97%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$19B
AUM Growth
+$4.37B
(+30%)
Cap. Flow
+$3.05B
Cap. Flow
% of AUM
16.07%
Top 10 Holdings %
Top 10 Hldgs %
39.91%
Holding
1,362
New
110
Increased
730
Reduced
452
Closed
64
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$492M |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$263M |
| 3 |
Qualcomm
QCOM
|
+$143M |
| 4 |
Broadcom
AVGO
|
+$118M |
| 5 |
iShares China Large-Cap ETF
FXI
|
+$105M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
VanEck Gold Miners ETF
GDX
|
+$81.8M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$18.6M |
| 3 |
Chevron
CVX
|
+$11.9M |
| 4 |
Xtrackers Harvest CSI 300 China A-Shares ETF
ASHR
|
+$10.9M |
| 5 |
ExxonMobil
XOM
|
+$8.22M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.28% |
| 2 | Financials | 15.39% |
| 3 | Healthcare | 5.04% |
| 4 | Energy | 4.05% |
| 5 | Consumer Discretionary | 2.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
326
DexCom
DXCM
$31.5B
| $5.73M | 0.03% |
42,712
-5,028
| -11% | -$722K |
|
|
CCXI
327
DELISTED
ChemoCentryx, Inc.
CCXI
| $5.72M | 0.03% |
157,221
-44,855
| -22% | -$1.57M |
|
328
Emergent Biosolutions
EBS
$373M
| $5.72M | 0.03% |
131,665
+77,075
| +141% | +$3.49M |
|
329
Gartner
IT
$10.1B
| $5.71M | 0.03% |
17,081
+1,867
| +12% | +$600K |
|
330
Ultragenyx Pharmaceutical
RARE
$2.45B
| $5.69M | 0.03% |
67,691
+37,052
| +121% | +$3.01M |
|
331
CSX Corp
CSX
$93.4B
| $5.68M | 0.03% |
151,167
-44,431
| -23% | -$1.57M |
|
332
Alkermes
ALKS
$8.22B
| $5.68M | 0.03% |
244,123
+142,027
| +139% | +$3.73M |
|
|
GBT
333
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $5.67M | 0.03% |
193,864
+78,480
| +68% | +$2.43M |
|
334
Protagonist Therapeutics
PTGX
$8.79B
| $5.67M | 0.03% |
165,772
+96,642
| +140% | +$3.05M |
|
335
Kosmos Energy
KOS
$1.6B
| $5.66M | 0.03% |
1,637,017
+599,461
| +58% | +$2.15M |
|
336
PTC Therapeutics
PTCT
$5.68B
| $5.66M | 0.03% |
142,153
+62,662
| +79% | +$2.4M |
|
337
Ligand Pharmaceuticals
LGND
$5.76B
| $5.66M | 0.03% |
58,723
+22,229
| +61% | +$2.05M |
|
338
Intellia Therapeutics
NTLA
$1.49B
| $5.66M | 0.03% |
47,854
+28,463
| +147% | +$3.57M |
|
|
HZNP
339
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.65M | 0.03% |
52,414
+23,496
| +81% | +$2.56M |
|
340
Honeywell
HON
$77B
| $5.64M | 0.03% |
28,703
-2,096
| -7% | -$423K |
|
341
Neurocrine Biosciences
NBIX
$16.8B
| $5.64M | 0.03% |
66,200
+33,986
| +106% | +$3.13M |
|
342
Everest Group
EG
$14.5B
| $5.62M | 0.03% |
20,509
+1,471
| +8% | +$398K |
|
343
Bristol-Myers Squibb
BMY
$133B
| $5.61M | 0.03% |
89,975
+6,985
| +8% | +$410K |
|
|
UMPQ
344
DELISTED
Umpqua Holdings Corp
UMPQ
| $5.6M | 0.03% |
291,159
+19,581
| +7% | +$395K |
|
345
CareDx
CDNA
$2.26B
| $5.58M | 0.03% |
122,744
+77,882
| +174% | +$4.07M |
|
346
Celldex Therapeutics
CLDX
$2.99B
| $5.57M | 0.03% |
144,115
+86,971
| +152% | +$3.79M |
|
|
DVAX
347
DELISTED
Dynavax Technologies
DVAX
| $5.57M | 0.03% |
395,583
+218,022
| +123% | +$3.59M |
|
348
Ironwood Pharmaceuticals
IRWD
$696M
| $5.56M | 0.03% |
476,786
+221,371
| +87% | +$2.72M |
|
349
Tradeweb Markets
TW
$21.4B
| $5.54M | 0.03% |
55,363
+4,967
| +10% | +$458K |
|
350
Veracyte
VCYT
$3.7B
| $5.54M | 0.03% |
134,450
+70,418
| +110% | +$3.11M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q4 2021 Portfolio in Review
As of Q4 2021, Rafferty Asset Management held 1,362 positions worth $19B, up 30% from $14.6B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Rafferty Asset Management deployed $3.05B of net new capital in Q4 2021, opening 110 new positions and adding to 730 existing holdings. Its largest new stake was Aflac: 345,009 shares worth $20.1M.
By sector, the portfolio is most concentrated in Technology at 35% of assets, up from 29% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was VanEck Gold Miners ETF, an estimated $81.8M trimmed.
- Rafferty Asset Management's largest Q4 2021 buy was Aflac: 345,009 shares worth $20.1M.
- Rafferty Asset Management added most to iShares Core S&P 500 ETF in Q4 2021, an estimated $492M increase.
- Rafferty Asset Management's biggest Q4 2021 reduction was VanEck Gold Miners ETF, cutting an estimated $81.8M.
- Rafferty Asset Management fully exited CIMAREX ENERGY CO in Q4 2021, selling an estimated $8.07M.
- Rafferty Asset Management's ten largest holdings make up 40% of its $19B portfolio in Q4 2021.
- Rafferty Asset Management opened 110 new positions and closed 64 in Q4 2021.
- Rafferty Asset Management's portfolio value rose 30% quarter-over-quarter to $19B.
Based on Rafferty Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.